China NMPA Drug Inspection - The Third Affiliated Hospital of Liaoning University of Traditional Chinese Medicine - Fuyi Shengjin Tablets

The Liaoning Provincial Drug Administration issued an announcement on November 28, 2019, detailing the findings of a province-wide drug quality sampling inspection. The inspection revealed that 25 batches of drugs, produced by 23 companies, including Hebei Yiren Pharmaceutical Co., Ltd., failed to meet regulatory standards. The primary issues identified were quality specification deficiencies in numerous traditional Chinese medicinal herbs, such as Yam, Moutan bark, Lycium bark, and Cirsium japonicum, from various manufacturers like Anhui Zehua Traditional Chinese Medicine Pieces Co., Ltd. and Hebei Liankang Pharmaceutical Co., Ltd. Additionally, some chemical products, specifically Norfloxacin capsules from Chengdu Jinhua Pharmaceutical Co., Ltd. and Glibenclamide tablets from Tianjin Pacific Pharmaceutical Co., Ltd., were cited for non-compliant labeling. A medical institution preparation, Fuyi Shengjin Tablets, also exhibited labeling discrepancies. In response, regulatory authorities initiated control measures, requiring sampled units to halt sales and usage of the affected batches. The administration also informed relevant provincial departments to handle non-compliant drugs from out-of-province manufacturers. All involved parties are mandated to investigate and penalize illegal activities in accordance with the "Drug Administration Law of the People's Republic of China" and other applicable regulations to safeguard public health.